Biofrontera AG successfully places capital increase
Biofrontera AG announces that the subscription of shares in the anticipated capital increase was closed. According to the current assessment the subscription of 1.2 million shares at a share price of € 1.50 is documented. The successful completion of the capital increase represents another relevant mile-stone in the financial stabilization of the Biofrontera group.
Already earlier in the year Biofrontera restructured its outstanding convertible bond. The major part was converted or transferred into a new option bond, running until December 2017 with a staggered coupon. In addition, the remaining convertible bond was extended until July 2012 and the coupon ceased for three years.
With the capital increase and after consideration of the effects of the restructuring of the convertible bond Biofrontera's base capital will increase to € 7,340,068 split into 7,340,068 shares.
The funds derived from the capital increase are required to reach the operative goals of the company and represent an important requirement for the aspired financial independence of the Biofrontera group. Important mile stones in the process are the market launch of the medical cosmetic Belixos®, foreseen for the fall 2009, and the completion of the clinical development of BF-200 ALA for the treatment of actinic keratosis.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Viral DNA in bacterial genome could hold key to novel cystic fibrosis treatments
Vitamin K may protect against developing non-Hodgkin's lymphoma, say Mayo Clinic researchers

New Salmonella Proteins Discovered - Only one small protein needs to be missing and salmonellae are no longer infectious

Cheaper mRNA Vaccines - Graz University of Technology Researchers Produce Pseudouridine through Biocatalytic Synthesis

Increased phosphate intake elevates blood pressure in healthy adults

AkzoNobel expands pharma salt production in Denmark
Actavis appoints Claudio Albrecht CEO

Contact lenses with medicine and sugar

Researchers develop nanoscale probes for ssDNA sustainability under UV radiation
ORCA Therapeutics Receives up to € 5 Million Innovation Credit from Dutch Government
GATC Biotech conducts research to detect cancer in women
